Remove Generic Pharmaceutical Remove HR Remove Medicine Remove Trials
article thumbnail

Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz

The Pharma Data

Q3 coreĀ¹ operating income grew +9% (cc, +10% USD) Innovative Medicines grew +13% (cc, +14% USD), due to higher sales and productivity programs Sandoz declined -15% (cc, -13% USD), impacted by gross margin Q3 operating income grew +32% (cc, +34% USD) Q3 net income increased +41% (cc, +43% USD) Q3 free cash flow 1 of USD 4.4 About Novartis.

article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. This is largely due to failed trials as a prophylaxis resulting in the European Committee for Medical Products (CHMP) recommending against the approval of Lagevrio.

Sales 98